These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18946890)

  • 21. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS
    Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
    Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.
    Shrikhande G; Khaodhiar L; Scali S; Lima C; Hubbard M; Dudley K; Ganda O; Ferran C; Veves A
    J Vasc Surg; 2006 Apr; 43(4):760-70; discussion 770-1. PubMed ID: 16616233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial.
    Lian F; Li G; Chen X; Wang X; Piao C; Wang J; Hong Y; Ba Z; Wu S; Zhou X; Lang J; Liu Y; Zhang R; Hao J; Zhu Z; Li H; Fang Liu H; Cao A; Yan Z; An Y; Bai Y; Wang Q; Zhen Z; Yu C; Wang CZ; Yuan CS; Tong X
    J Clin Endocrinol Metab; 2014 Feb; 99(2):648-55. PubMed ID: 24432995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
    Maggioni AP; Fabbri G
    Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes prevention: can insulin secretagogues do the job?
    Westerhaus B; Gosmanov AR; Umpierrez GE
    Prim Care Diabetes; 2011 Jul; 5(2):73-80. PubMed ID: 21185798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of nateglinide in the management of patients with type 2 diabetes.
    Tentolouris N; Voulgari C; Katsilambros N
    Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
    Bellomo Damato A; Stefanelli G; Laviola L; Giorgino R; Giorgino F
    Diabet Med; 2011 May; 28(5):560-6. PubMed ID: 21204958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 36. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
    Cohn JN; Tognoni G; Glazer RD; Spormann D; Hester A
    J Card Fail; 1999 Jun; 5(2):155-60. PubMed ID: 10404355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin stimulation by nateglinide in IGT subjects.
    Hirose T; Mizuno R; Yoshimoto T
    Endocr J; 2002 Dec; 49(6):649-52. PubMed ID: 12625415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.
    Khaodhiar L; Brennan AM; Lima C; Chan JL; Mantzoros CS; Manning WJ; Danias PG; Veves A
    Metabolism; 2009 May; 58(5):682-8. PubMed ID: 19375592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
    Currie G; Bethel MA; Holzhauer B; Haffner SM; Holman RR; McMurray JJV
    Diabetes Obes Metab; 2017 Jun; 19(6):791-799. PubMed ID: 28093841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.